Study details
Enrolling now
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics, Inc.
NCT IDNCT07012395ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
645
Study length
about 2.8 years
Ages
18+
Locations
21 sites in CA, CO, FL +10
About this study
Researchers are testing a new treatment, SPY001, SPY002, or SPY003, alone or in combination with a placebo, for people with moderate to severe ulcerative colitis. The trial will last 1039 days and involve approximately 645 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take SPY001
- 3.Take SPY002
- +1 more
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Gastroenterology